nach oben

Current Atherosclerosis Reports

Erschienen in:

14.05.2021 | SARS-CoV-2 | Coronary Heart Disease (S. Virani and S. Naderi, Section Editors) Zur Zeit gratis

COVID and Cardiovascular Disease: What We Know in 2021

verfasst von: Michael Chilazi, Eamon Y. Duffy, Aarti Thakkar, Erin D. Michos

Erschienen in: Current Atherosclerosis Reports | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Coronavirus disease 2019 (COVID-19) has been the cause of significant global morbidity and mortality. Here, we review the literature to date of the short-term and long-term consequences of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection on the heart.

Recent Findings

Early case reports described a spectrum of cardiovascular manifestations of COVID-19, including myocarditis, stress cardiomyopathy, myocardial infarction, and arrhythmia. However, in most cases, myocardial injury in COVID-19 appears to be predominantly mediated by the severity of critical illness rather than direct injury to myocardium from viral particles. While cardiac magnetic resonance imaging remains a powerful tool for diagnosing acute myocarditis, it should be used judiciously in light of low baseline prevalence of myocarditis. Guiding an athletic patient through return to play (RTP) after COVID-19 infection is a challenging process. More recent data show RTP has been a safe endeavor using a screening protocol. “Long COVID” or post-acute sequelae of SARS-CoV-2 infection has also been described. The reported symptoms span a large breadth of cardiopulmonary and neurologic complaints including fatigue, palpitations, chest pain, breathlessness, brain fog, and dysautonomia including postural tachycardia syndrome (POTS). Management of POTS/dysautonomia primarily centers on education, exercise, and salt and fluid repletion.

Summary

Our understanding of the impact of COVID-19 on the cardiovascular system is constantly evolving. As we enter a new age of survivorship, additional research is needed to catalogue the burden of persistent cardiopulmonary symptoms. Research is also needed to learn how acute management may alter the likelihood and prevalence of this chronic syndrome.

Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021. https://doi.org/10.1001/jama.2021.5469.

2•.

Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141(23):1903–14. https://doi.org/10.1161/CIRCULATIONAHA.120.047349This was one of the first papers to describe acute cardiovascular presentations of COVID-19 infection from epidemiology, pathogenesis, diagnosis, and treatment.CrossRefPubMedPubMedCentral

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–55. https://doi.org/10.1161/CIRCULATIONAHA.120.046941.CrossRefPubMed

Khan MS, Shahid I, Anker SD, Solomon SD, Vardeny O, Michos ED, et al. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 2020;18(1):403. https://doi.org/10.1186/s12916-020-01816-2.CrossRefPubMedPubMedCentral

Duffy EY, Cainzos-Achirica M, Michos ED. Primary and secondary prevention of cardiovascular disease in the era of the coronavirus pandemic. Circulation. 2020;141(24):1943–5. https://doi.org/10.1161/CIRCULATIONAHA.120.047194.CrossRefPubMedPubMedCentral

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8. https://doi.org/10.1001/jamacardio.2020.1017.CrossRefPubMed

Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518–36. https://doi.org/10.1016/j.jacbts.2020.04.002.CrossRefPubMedPubMedCentral

8•.

Usman MS, Siddiqi TJ, Khan MS, Ahmed A, Ali SS, Michos ED, et al. A Meta-analysis of the relationship between renin-angiotensin-aldosterone system inhibitors and COVID-19. Am J Cardiol. 2020;130:159–61. https://doi.org/10.1016/j.amjcard.2020.05.038Addressing some hypothetical concerns raised early in the pandemic, this meta-analysis provided reassurance that there was no excess risk seen with the use of ACE inhibitors and angiotensin receptor blockers in the setting of COVID-19, and that patients prescribed these medications should continue to use them.CrossRefPubMedPubMedCentral

Minhas AS, Scheel P, Garibaldi B, Liu G, Horton M, Jennings M, et al. Takotsubo syndrome in the setting of COVID-19. JACC Case Rep. 2020;2(9):1321–5. https://doi.org/10.1016/j.jaccas.2020.04.023.CrossRefPubMedPubMedCentral

10.

Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020;141(23):1930–6. https://doi.org/10.1161/CIRCULATIONAHA.120.047164.CrossRefPubMedPubMedCentral

11.

Dherange P, Lang J, Qian P, Oberfeld B, Sauer WH, Koplan B, et al. Arrhythmias and COVID-19: a review. JACC Clin Electrophysiol. 2020;6(9):1193–204. https://doi.org/10.1016/j.jacep.2020.08.002.CrossRefPubMedPubMedCentral

12.

Castiello T, Georgiopoulos G, Finocchiaro G, Claudia M, Gianatti A, Delialis D, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2021. https://doi.org/10.1007/s10741-021-10087-9.

13.

Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–73. https://doi.org/10.1001/jamacardio.2020.3557.CrossRefPubMedPubMedCentral

14.

Goerlich E, Minhas AS, Mukherjee M, Sheikh FH, Gilotra NA, Sharma G, et al. Multimodality imaging for cardiac evaluation in patients with COVID-19. Curr Cardiol Rep. 2021;23(5):44. https://doi.org/10.1007/s11886-021-01483-6.CrossRefPubMedPubMedCentral

15.

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618–e51. https://doi.org/10.1161/CIR.0000000000000617.CrossRefPubMed

16.

Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345–53. https://doi.org/10.1056/NEJMoa1702090.CrossRefPubMed

17•.

Chapman AR, Bularga A, Mills NL. High-sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation. 2020;141(22):1733–5. https://doi.org/10.1161/CIRCULATIONAHA.120.047008This short article summarizes the various mechanisms of myocardial injury in COVID-19 that lead to elevation in cardiac troponin levels.CrossRefPubMed

18.

Jaffe AS, Cleland JGF, Katus HA. Myocardial injury in severe COVID-19 infection. Eur Heart J. 2020;41(22):2080–2. https://doi.org/10.1093/eurheartj/ehaa447.CrossRefPubMed

19.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10. https://doi.org/10.1001/jamacardio.2020.0950.CrossRefPubMedPubMedCentral

20.

Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070–9. https://doi.org/10.1093/eurheartj/ehaa408.CrossRefPubMed

21.

Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390–1. https://doi.org/10.1016/j.pcad.2020.03.001.CrossRefPubMedPubMedCentral

22.

Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Special article - Acute myocardial injury in patients hospitalized with COVID-19 infection: a review. Prog Cardiovasc Dis. 2020;63(5):682–9. https://doi.org/10.1016/j.pcad.2020.05.013.CrossRefPubMedPubMedCentral

23.

Heffernan KS, Michos ED, Gump BB. Coronavirus disease 2019 (COVID-19) and cardiac injury. JAMA Cardiol. 2020;5:1198. https://doi.org/10.1001/jamacardio.2020.2450.CrossRefPubMed

24•.

Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533–46. https://doi.org/10.1016/j.jacc.2020.06.007This large study of over 2700 hospitalized patients with COVID highlighted the adverse prognosis associated with myocardial injury in the setting of COVID. The study showed that even after accounting for disease severity and clinical risk factors, even small elevations in cardiac troponin were associated with a 1.75× increased risk of death, and larger elevation of troponin associated with threefold risk of death.CrossRefPubMedPubMedCentral

25.

Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, et al. Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: Results of a Multicenter Study. JAMA Cardiol. 2020;5(11):1274–80. https://doi.org/10.1001/jamacardio.2020.3538.CrossRefPubMed

26.

Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Investig. 2009;39(7):618–25. https://doi.org/10.1111/j.1365-2362.2009.02153.x.CrossRef

27.

Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020;3(4):e205619. https://doi.org/10.1001/jamanetworkopen.2020.5619.CrossRefPubMedPubMedCentral

28.

Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail. 2020;22(12):2238–47. https://doi.org/10.1002/ejhf.2052.CrossRefPubMed

29.

Hosseinzadeh R, Goharrizi M, Bahardoust M, Alvanegh AG, Ataee MR, Bagheri M, et al. Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)? Clin Hypertens. 2021;27(1):3. https://doi.org/10.1186/s40885-021-00161-7.CrossRefPubMedPubMedCentral

30.

Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–92. https://doi.org/10.1016/S2213-8587(20)30238-2.CrossRefPubMedPubMedCentral

31.

Hendren NS, de Lemos JA, Ayers C, Das SR, Rao A, Carter S, et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2021;143(2):135–44. https://doi.org/10.1161/CIRCULATIONAHA.120.051936.CrossRefPubMed

32••.

Lindner D, Fitzek A, Brauninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5(11):1281–5. https://doi.org/10.1001/jamacardio.2020.3551Contrary to prior speculations, this study showed that SARS-CoV-2 is unlikely to be causing myocardial injury through direct myocardial invasion. The authors found that while viral RNA was isolated in cardiac tissue, in situ hybridization localized the site of infection not to cardiomyocytes, but rather to the interstitium and infiltrating macrophages. Additionally, there were zero confirmed cases of myocarditis by Dallas criteria.CrossRefPubMed

33.

Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681–6. https://doi.org/10.1016/S2213-2600(20)30243-5.CrossRefPubMedPubMedCentral

34.

Bois MC, Boire NA, Layman AJ, Aubry MC, Alexander MP, Roden AC, et al. COVID-19-associated nonocclusive fibrin microthrombi in the heart. Circulation. 2021;143(3):230–43. https://doi.org/10.1161/CIRCULATIONAHA.120.050754.CrossRefPubMed

35••.

Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial injury in severe COVID-19 compared with non-COVID-19 acute respiratory distress syndrome. Circulation. 2021;143(6):553–65. https://doi.org/10.1161/CIRCULATIONAHA.120.050543This study challenged prior notions that myocardial injury was more common in COVID-19 than other critical illnesses. This study compared troponin elevation in COVID-19 ARDS vs non-COVID-19 ARDS among nearly 250 intubated patients across a large hospital system and demonstrated that myocardial injury was actually less common in COVID-19 than non-COVID-19 ARDS, after accounting for the degree of critical illness and organ dysfunction.CrossRefPubMed

36.

Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. J Am Coll Cardiol. 2020;76(10):1244–58. https://doi.org/10.1016/j.jacc.2020.06.068.CrossRefPubMedPubMedCentral

37.

Metkus TS, Guallar E, Sokoll L, Morrow D, Tomaselli G, Brower R, et al. Prevalence and prognostic association of circulating troponin in the acute respiratory distress syndrome. Crit Care Med. 2017;45(10):1709–17. https://doi.org/10.1097/CCM.0000000000002641.CrossRefPubMedPubMedCentral

38.

Metkus TS, Guallar E, Sokoll L, Morrow DA, Tomaselli G, Brower R, et al. Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome. J Crit Care. 2018;48:26–31. https://doi.org/10.1016/j.jcrc.2018.08.009.CrossRefPubMedPubMedCentral

39.

Masson S, Caironi P, Fanizza C, Carrer S, Caricato A, Fassini P, et al. Sequential N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin measurements during albumin replacement in patients with severe sepsis or septic shock. Crit Care Med. 2016;44(4):707–16. https://doi.org/10.1097/CCM.0000000000001473.CrossRefPubMed

40.

Li D, Chen Y, Jia Y, Tong L, Tong J, Wang W, et al. SARS-CoV-2-induced immune dysregulation and myocardial injury risk in China: insights from the ERS-COVID-19 study. Circ Res. 2020;127(3):397–9. https://doi.org/10.1161/CIRCRESAHA.120.317070.CrossRefPubMed

41.

Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139(6):713–27. https://doi.org/10.1309/AJCP4ZDKJ4ICOUAT.CrossRefPubMed

42.

Perez AL, Grodin JL, Chaikijurajai T, Wu Y, Hernandez AF, Butler J, et al. Interleukin-6 and outcomes in acute heart failure: an ASCEND-HF substudy. J Card Fail. 2021. https://doi.org/10.1016/j.cardfail.2021.01.006.

43.

Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation. 2020;142(4):342–53. https://doi.org/10.1161/CIRCULATIONAHA.120.047971.CrossRefPubMedPubMedCentral

44.

Giustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vicenzi M, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2043–55. https://doi.org/10.1016/j.jacc.2020.08.069.CrossRefPubMedPubMedCentral

45.

Goerlich E, Gilotra NA, Minhas AS, Bavaro N, Hays AG, Cingolani OH. Prominent longitudinal strain reduction of basal left ventricular segments in patients with coronavirus disease-19. J Card Fail. 2021;27(1):100–4. https://doi.org/10.1016/j.cardfail.2020.09.469.CrossRefPubMed

46.

Smilowitz NR, Jethani N, Chen J, Aphinyanaphongs Y, Zhang R, Dogra S, et al. Myocardial injury in adults hospitalized with COVID-19. Circulation. 2020;142(24):2393–5. https://doi.org/10.1161/CIRCULATIONAHA.120.050434.CrossRefPubMedPubMedCentral

47.

Qin JJ, Cheng X, Zhou F, Lei F, Akolkar G, Cai J, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension. 2020;76(4):1104–12. https://doi.org/10.1161/HYPERTENSIONAHA.120.15528.CrossRefPubMed

48.

Stefanini GG, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512–8. https://doi.org/10.1136/heartjnl-2020-317322.CrossRefPubMed

49.

Sanghvi SK, Schwarzman LS, Nazir NT. Cardiac MRI and myocardial injury in COVID-19: diagnosis, risk stratification and prognosis. Diagnostics. 2021;11(1). https://doi.org/10.3390/diagnostics11010130.

50.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8. https://doi.org/10.1007/s00134-020-05991-x.CrossRefPubMed

51.

Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–71. https://doi.org/10.1016/j.jacc.2020.03.031.CrossRefPubMedPubMedCentral

52.

Lagana N, Cei M, Evangelista I, Cerutti S, Colombo A, Conte L, et al. Suspected myocarditis in patients with COVID-19: a multicenter case series. Medicine. 2021;100(8):e24552. https://doi.org/10.1097/MD.0000000000024552.CrossRefPubMedPubMedCentral

53.

Skulstad H, Cosyns B, Popescu BA, Galderisi M, Salvo GD, Donal E, et al. COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel. Eur Heart J Cardiovasc Imaging. 2020;21(6):592–8. https://doi.org/10.1093/ehjci/jeaa072.CrossRefPubMed

54.

Han Y, Chen T, Bryant J, Bucciarelli-Ducci C, Dyke C, Elliott MD, et al. Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic. J Cardiovasc Magn Reson. 2020;22(1):26. https://doi.org/10.1186/s12968-020-00628-w.CrossRefPubMedPubMedCentral

55•.

Rudski L, Januzzi JL, Rigolin VH, Bohula EA, Blankstein R, Patel AR, et al. Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020;76(11):1345–57. https://doi.org/10.1016/j.jacc.2020.06.080This expert panel from the ACC recommends CMR only after CAD has been ruled out by angiography or less invasive modalities, such as CCTA, because the pre-test probability of ischemia is much more likely than acute myocarditis.CrossRefPubMedPubMedCentral

56.

Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging. 2020;13(11):2330–9. https://doi.org/10.1016/j.jcmg.2020.05.004.CrossRefPubMedPubMedCentral

57.

Siddiqui Y, Crouser ED, Raman SV. Nonischemic myocardial changes detected by cardiac magnetic resonance in critical care patients with sepsis. Am J Respir Crit Care Med. 2013;188(8):1037–9. https://doi.org/10.1164/rccm.201304-0744LE.CrossRefPubMedPubMedCentral

58.

Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119(8):1085–92. https://doi.org/10.1161/CIRCULATIONAHA.108.804617.CrossRefPubMed

59.

La Gerche A, Taylor AJ, Prior DL. Athlete’s heart: the potential for multimodality imaging to address the critical remaining questions. JACC Cardiovasc Imaging. 2009;2(3):350–63. https://doi.org/10.1016/j.jcmg.2008.12.011.CrossRefPubMed

60.

Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol. 2010;56(3):169–76. https://doi.org/10.1016/j.jacc.2010.03.037.CrossRefPubMed

61.

Phelan D, Kim JH, Chung EH. A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection. JAMA Cardiol. 2020;5:1085–6. https://doi.org/10.1001/jamacardio.2020.2136.CrossRefPubMed

62.

Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NA 3rd, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132(22):e273–80. https://doi.org/10.1161/CIR.0000000000000239.CrossRefPubMed

63.

Kim JH, Levine BD, Phelan D, Emery MS, Martinez MW, Chung EH, et al. Coronavirus disease 2019 and the athletic heart: emerging perspectives on pathology, risks, and return to play. JAMA Cardiol. 2021;6(2):219–27. https://doi.org/10.1001/jamacardio.2020.5890.CrossRefPubMed

64.

Phelan D, Kim JH, Elliott MD, Wasfy MM, Cremer P, Johri AM, et al. Screening of potential cardiac involvement in competitive athletes recovering from COVID-19: An Expert Consensus Statement. JACC Cardiovasc Imaging. 2020;13(12):2635–52. https://doi.org/10.1016/j.jcmg.2020.10.005.CrossRefPubMedPubMedCentral

65.

Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021;6(1):116–8. https://doi.org/10.1001/jamacardio.2020.4916.CrossRefPubMed

66.

Brito D, Meester S, Yanamala N, Patel HB, Balcik BJ, Casaclang-Verzosa G, et al. High prevalence of pericardial involvement in college student athletes recovering from COVID-19. JACC Cardiovasc Imaging. 2021;14(3):541–55. https://doi.org/10.1016/j.jcmg.2020.10.023.CrossRefPubMed

67••.

Martinez MW, Tucker AM, Bloom OJ, Green G, DiFiori JP, Solomon G, et al. Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening. JAMA Cardiol. 2021. https://doi.org/10.1001/jamacardio.2021.0565This reassuring registry data showed that the national return to play for athletes has been a safe endeavor. This study of 789 professional athletes that underwent a RTP cardiac testing protocol after COVID-19 infection found imaging evidence of inflammatory heart disease in only 0.6%.

68.

Couzin-Frankel J. The long haul. Science. 2020;369(6504):614–7. https://doi.org/10.1126/science.369.6504.614.CrossRefPubMed

69.

Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. https://doi.org/10.1136/bmj.m3026.CrossRefPubMed

70.

Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med. 2021;21(1):e63–e7. https://doi.org/10.7861/clinmed.2020-0896.CrossRef

71.

National Institute of Health. https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid. Accessed April 5, 2020.

72.

Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93(2):1013–22. https://doi.org/10.1002/jmv.26368.CrossRefPubMed

73.

Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993–8. https://doi.org/10.15585/mmwr.mm6930e1.CrossRefPubMedPubMedCentral

74.

Lo YL. COVID-19, fatigue, and dysautonomia. J Med Virol. 2021;93(3):1213. https://doi.org/10.1002/jmv.26552.CrossRefPubMed

75.

Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15. https://doi.org/10.1038/s41591-021-01283-z.CrossRefPubMedPubMedCentral

76.

Carfi A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–5. https://doi.org/10.1001/jama.2020.12603.CrossRefPubMedPubMedCentral

77•.

Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2020. https://doi.org/10.7326/M20-5661This study evaluating patients 60 days after COVID-19 hospitalization identified that a significant proportion of patients still had residual symptoms, as well as mental and financial stressors. This study highlights that for many patients, it is not over after their discharge home.

78.

Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science. 2020;368(6497):1362–7. https://doi.org/10.1126/science.abc0473.CrossRefPubMedPubMedCentral

79.

Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al. Attributes and predictors of long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. 2020:2020.10.19.20214494. https://doi.org/10.1101/2020.10.19.20214494.

80.

Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258–63. https://doi.org/10.1016/j.cmi.2020.09.052.CrossRefPubMed

81.

Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7(1):9110. https://doi.org/10.1038/s41598-017-09536-z.CrossRefPubMedPubMedCentral

82.

Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831–40. https://doi.org/10.1001/jamacardio.2020.1286.CrossRefPubMed

83•.

Johansson M, Stahlberg M, Runold M, Nygren-Bonnier M, Nilsson J, Olshansky B, et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic Tachycardia syndrome: the Swedish experience. JACC Case Rep. 2021. https://doi.org/10.1016/j.jaccas.2021.01.009This case series called attention to a rising number of patients and case studies with postural tachycardia syndrome (POTS) following COVID-19.

84.

Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019;285(4):352–66. https://doi.org/10.1111/joim.12852.CrossRefPubMed

85.

Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm. 2021;18(4):508–9. https://doi.org/10.1016/j.hrthm.2020.12.007.CrossRefPubMed

86.

Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. Postural orthostatic tachycardia syndrome: JACC focus seminar. J Am Coll Cardiol. 2019;73(10):1207–28. https://doi.org/10.1016/j.jacc.2018.11.059.CrossRefPubMed

87.

George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009–16. https://doi.org/10.1136/thoraxjnl-2020-215314.CrossRefPubMed

Titel: COVID and Cardiovascular Disease: What We Know in 2021
verfasst von: Michael Chilazi
Eamon Y. Duffy
Aarti Thakkar
Erin D. Michos
Publikationsdatum: 14.05.2021
Verlag: Springer US
Schlagwörter: SARS-CoV-2
COVID-19
Erschienen in: Current Atherosclerosis Reports / Ausgabe 7/2021
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-021-00935-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

COVID and Cardiovascular Disease: What We Know in 2021

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Sustainable Diets for Cardiovascular Disease Prevention and Management

Apolipoprotein E and Atherosclerosis

Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies

HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis

Sodium and Health Outcomes: Ascertaining Valid Estimates in Research Studies

MicroRNAs and Circular RNAs in Lipoprotein Metabolism

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin